Skip to content

Study · Measured the body's own peptide · 2026

6 results

Circulating Humanin Improves the Prognostic Accuracy of Cardiovascular Risk Models in Chronic Hemodialysis Patients.

Bolignano D, Greco M, Pugliese S, Duni A, Presta P, Errante A, Pappas E, Lakkas L, Misiti R, Naka KK, Foti DP, Andreucci M, Coppolino G, Dounousi E

Cardiorenal medicine18 Mar 2026

PMID41849628 (opens in a new tab)PMCIDPMC13193688 (opens in a new tab)DOI10.1159/000551517 (opens in a new tab)PepBankPUB-41849628
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Natural levels measured6

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    In chronic hemodialysis patients, circulating humanin had a curvilinear association with cardiovascular morbidity and mortality, with both low and high levels linked to increased risk.

    In plain wordsIn dialysis patients, both low and high natural humanin levels in blood were linked to more heart and vessel events.

    Peptide
    Humanin
    Outcome
    MixedAssociation of circulating humanin with cardiovascular morbidity and mortality
    Study

    n = 83

    Outcome group
    Cardiovascular events · Cardiovascular

    Measurements

    Low humanin threshold
    < 462 pg/mL
    increased CVMM risk
    High humanin threshold
    > 778 pg/mL
    increased CVMM risk

    Source sentences

    Summary
    Humanin displayed a curvilinear association with CVMM, with both low (778 pg/mL) levels linked to an increased risk.
    1 context sentence
    Summary · context
    Eighty-three chronic HD patients (mean age 67 ± 12 years; 74.7% male) were enrolled in a 24-month prospective multicenter study.

    This result measures the body's own Humanin. Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelObservational studyOther

    In chronic hemodialysis patients, adding humanin improved discrimination of all cardiovascular risk models.

    In plain wordsIn dialysis patients, adding natural humanin levels to heart risk models improved how well they told apart patients with and without events.

    Peptide
    Humanin
    Outcome
    IncreaseDiscrimination of risk models with humanin (delta AUC)
    Study

    n = 83

    Outcome group
    Cardiovascular events · Cardiovascular

    Measurements

    Delta AUC
    0.083 to 0.109
    all models

    Source sentences

    Summary
    Humanin inclusion remarkably improved discrimination (ΔAUC spanning from 0.083 to 0.109)
    1 context sentence
    Summary · context
    Eighty-three chronic HD patients (mean age 67 ± 12 years; 74.7% male) were enrolled in a 24-month prospective multicenter study.

    This result measures the body's own Humanin. Nobody was given the peptide. It is not evidence about taking it.

  3. 03HumanEndogenous levelObservational studyOther

    In chronic hemodialysis patients, adding humanin improved calibration of all cardiovascular risk models.

    In plain wordsIn dialysis patients, adding natural humanin levels to heart risk models improved how closely predicted risks matched real events.

    Peptide
    Humanin
    Outcome
    IncreaseCalibration of risk models with humanin
    Study

    n = 83

    Outcome group
    Cardiovascular events · Cardiovascular

    Source sentences

    Summary
    Humanin inclusion remarkably improved discrimination (ΔAUC spanning from 0.083 to 0.109), calibration
    1 context sentence
    Summary · context
    Eighty-three chronic HD patients (mean age 67 ± 12 years; 74.7% male) were enrolled in a 24-month prospective multicenter study.

    This result measures the body's own Humanin. Nobody was given the peptide. It is not evidence about taking it.

  4. 04HumanEndogenous levelObservational studyOther

    In chronic hemodialysis patients, adding humanin raised explained variance of all cardiovascular risk models, with an R2 gain from 9 to 15%.

    In plain wordsIn dialysis patients, adding natural humanin levels to heart risk models raised the share of risk they explained by 9 to 15%.

    Peptide
    Humanin
    Outcome
    IncreaseExplained variance of risk models with humanin (R2 gain)
    Study

    n = 83

    Outcome group
    Cardiovascular events · Cardiovascular

    Source sentences

    Summary
    explained variance (R2 gain from 9 to 15%)
    1 context sentence
    Summary · context
    Eighty-three chronic HD patients (mean age 67 ± 12 years; 74.7% male) were enrolled in a 24-month prospective multicenter study.

    This result measures the body's own Humanin. Nobody was given the peptide. It is not evidence about taking it.

  5. 05HumanEndogenous levelObservational studyOther

    In chronic hemodialysis patients, adding humanin improved reclassification of all cardiovascular risk models, with a Net Reclassification Improvement of 8-27.9%.

    In plain wordsIn dialysis patients, adding natural humanin levels to heart risk models moved more patients into the right risk group.

    Peptide
    Humanin
    Outcome
    IncreaseNet Reclassification Improvement with humanin
    Study

    n = 83

    Outcome group
    Cardiovascular events · Cardiovascular

    Measurements

    Net Reclassification Improvement
    8 to 27.9%
    all models

    Source sentences

    Summary
    Net Reclassification Improvement: 8-27.9%
    1 context sentence
    Summary · context
    Eighty-three chronic HD patients (mean age 67 ± 12 years; 74.7% male) were enrolled in a 24-month prospective multicenter study.

    This result measures the body's own Humanin. Nobody was given the peptide. It is not evidence about taking it.

  6. 06HumanEndogenous levelObservational studyOther

    In chronic hemodialysis patients, adding humanin improved the Integrated Discrimination Index of all cardiovascular risk models, by 4.4-7.3%.

    In plain wordsIn dialysis patients, adding natural humanin levels to heart risk models improved how well they separated high-risk from low-risk patients.

    Peptide
    Humanin
    Outcome
    IncreaseIntegrated Discrimination Index with humanin
    Study

    n = 83

    Outcome group
    Cardiovascular events · Cardiovascular

    Measurements

    Integrated Discrimination Index
    4.4 to 7.3%
    all models

    Source sentences

    Summary
    Integrated Discrimination Index: 4.4-7.3%
    1 context sentence
    Summary · context
    Eighty-three chronic HD patients (mean age 67 ± 12 years; 74.7% male) were enrolled in a 24-month prospective multicenter study.

    This result measures the body's own Humanin. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.